Latest News on Pfizer Inc. (PFE) Stock

  • BMO Capital Markets Analysts Give Pfizer Inc. (PFE) a $33.00 Price Target [December 5 2016 05:39 AM]
  • BMO Capital Markets Analysts Give Pfizer Inc. (PFE) a $33.00 Price Target   BBNS - 56 minutes ago Pfizer Inc. logo BMO Capital Markets set a $33.00 price target on Pfizer Inc. (NYSE:PFE) in a research note released on Wednesday. Advisory Services Network LLC Purchases 5366 Shares of Pfizer Inc. (PFE) - The Cerbat Gem  Earnings Take Center Stage; Analysts Weighing in on Pfizer, Inc. (N... Read more about this Pfizer Inc. (PFE) news
  • Analysts Upside For This Dividend Diamond: Pfizer Inc. (NYSE:PFE) [December 5 2016 05:16 AM]
  • Analysts Upside For This Dividend Diamond: Pfizer Inc. (NYSE:PFE)   CSZ News - 1 hour ago If investors are looking for a stable dividend stock with upside, Pfizer Inc. (NYSE:PFE) could be one that fits the bill. The stock currently provides a dividend yield of 3.79% for the Healthcare company. Read more about this Pfizer Inc. (PFE) news


  • Pfizer Inc. (NYSE:PFE) & American Express Company (NYSE:AXP) Worth Watching Stocks [December 5 2016 04:31 AM]
  • Pfizer Inc. (NYSE:PFE) & American Express Company (NYSE:AXP) Worth Watching Stocks   Money News - 2 hours ago On Friday, Shares of Pfizer Inc. (NYSE:PFE) gained 0.54% to $31.63. The share price is trading in a range of $31.36 - 31.73. Pfizer Inc. (NYSE:PFE) reports new Phase 2 results show investigational ... - KC Register  Read more about this Pfizer Inc. (PFE) news


  • Stocks End Week Mixed, How Did This Name Fare: Pfizer Inc. (NYSE:PFE) [December 2 2016 02:30 PM]
  • Stocks End Week Mixed, How Did This Name Fare: Pfizer Inc. (NYSE:PFE)   Engelwood Daily - Dec 2, 2016 Pfizer Inc. (NYSE:PFE) closed at $31.63 after seeing 18979595 shares trade hands during the most recent session. This represents a change of 0.29% from the opening. Read more about this Pfizer Inc. (PFE) news
  • Pfizer's blood cancer drug Bosulif effective in untreated patients [December 5 2016 05:43 AM]
  • [Reuters] - Pfizer Inc said on Monday its cancer drug, Bosulif, was found effective in a late-stage study on previously untreated patients with a form of blood and bone marrow cancer that is characterized by the abnormal production of white blood cells. Most people with chronic myeloid leukemia (CML) have a genetic mutation, called the Philadelphia chromosome, which causes the bone marrow to make ... Read more about this Pfizer Inc. (PFE) news
  • Pfizer and Avillion Announce Positive Top-Line Results for Phase 3 BFORE Study of BOSULIF for First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia [December 5 2016 05:00 AM]
  • [Business Wire] - Today, Pfizer Inc. and its partner Avillion LLP announced results from the Phase 3 BFORE trial demonstrating superiority of BOSULIF┬« over imatinib as a first-line treatment for patients with chronic phase Philadelphia chromosome positive chronic myeloid leukemia . Read more about this Pfizer Inc. (PFE) news

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center